Dr. Shah is an assistant professor in lymphoma division at HCI since 2019. His practice includes NHL, HL, and CLL. His research focuses on real-world outcomes of lymphoma patients, racial disparity and development of novel targeted agents for refractory lymphoma patients. He is a recipient of LSRMP award for a clinical trial which focuses on improving outcomes of patients with progression on anti-PD-1 agents with utilization of novel agents.